https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-26 / Gene Ther. 2009 Jun;16(6):796-804
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-26 / Gene Ther. 2009 Jun;16(6):796-8042009-02-26 00:00:002009-02-26 00:00:00Genetically engineered Newcastle disease virus for malignant melanoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-20 / J. Dermatol. Sci. 2009 Apr;54(1):31-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-20 / J. Dermatol. Sci. 2009 Apr;54(1):31-72009-01-20 00:00:002019-02-15 08:49:30Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-12 / J. Clin. Oncol. 2009 Feb;27(6):945-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-12 / J. Clin. Oncol. 2009 Feb;27(6):945-522009-01-12 00:00:002019-02-15 08:49:55Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-12-13 / Cancer Immunol. Immunother. 2009 Dec;58(12):1935-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-12-13 / Cancer Immunol. Immunother. 2009 Dec;58(12):1935-92008-12-13 00:00:002008-12-13 00:00:00Mechanisms of murine dendritic cell antitumor dysfunction in aging
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-412008-11-27 00:00:002019-02-15 09:19:13Dendritic cells in the skin–potential use for melanoma treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-502008-11-15 00:00:002019-02-15 09:19:16Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-15 / Clin. Cancer Res. 2008 Nov;14(22):7358-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-15 / Clin. Cancer Res. 2008 Nov;14(22):7358-662008-11-15 00:00:002019-02-15 09:19:17Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-82008-11-01 00:00:002019-02-15 09:19:15[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-403
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-4032008-10-23 00:00:002019-02-15 09:19:13The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-08 / Clin. Immunol. 2008 Dec;129(3):482-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-08 / Clin. Immunol. 2008 Dec;129(3):482-912008-10-08 00:00:002019-02-15 09:19:18Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model
